Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T in Refractory Myasthenia Gravis
NCT05828225Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital) in myasthenia gravis (MG), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days, Treatment-emergent adverse events at 90 days and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital)
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05828225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828225.